Get the Stockscreener App
147.83
1.47%
-2.20
After Hours:
147.07
-0.76
-0.51%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $147.83, with a volume of 6.49M.
It is down -1.47% in the last 24 hours and up +3.18% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$150.03
Open:
$148.13
24h Volume:
6.49M
Relative Volume:
0.91
Market Cap:
$183.52B
Revenue:
$29.45B
Net Income/Loss:
$8.51B
P/E Ratio:
21.80
EPS:
6.7823
Net Cash Flow:
$9.46B
1W Performance:
+0.13%
1M Performance:
+3.18%
6M Performance:
+30.83%
1Y Performance:
+27.45%
1-Day Range:
$145.52
$148.84
1-Week Range:
$143.09
$150.77
52-Week Range:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
147.83 | 186.25B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
1,007.73 | 909.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.75 | 599.00B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
233.86 | 414.21B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
164.18 | 318.41B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
201.76 | 315.94B | 58.80B | 10.24B | 8.98B | 3.2788 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences (NASDAQ:GILD) Navigates Market Shifts Within The Nasdaq Composite - Kalkine Media
Gilead Sciences (NASDAQ:GILD) Stock Acquired Rep. Josh Gottheimer - MarketBeat
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead Sciences Insider Sold Shares Worth $1,447,859, According to a Recent SEC Filing - marketscreener.com
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia - Business Wire
Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S - TradingView
Gilead Sciences, Inc. $GILD Shares Sold by APG Asset Management N.V. - MarketBeat
Assessing Gilead Sciences (GILD) Valuation As Recent Share Price Momentum Meets Conflicting Fair Value Signals - Yahoo Finance
Gilead Sciences, Inc. $GILD Holdings Cut by Rafferty Asset Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by DNB Asset Management AS - MarketBeat
Argent Trust Co Buys 21,785 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange By Investing.com - Investing.com South Africa
P/E Ratio Insights for Gilead Sciences - Benzinga
Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know - TradingKey
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and moreMM+MMedical Marketing and Media - Medical Marketing and Media
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector? - Barchart.com
Handelsbanken Fonder AB Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Q3 EPS Estimates for Gilead Sciences Cut by Zacks Research - MarketBeat
MAI Capital Management Purchases 13,649 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Erste Asset Management GmbH Sells 30,299 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Clifford Swan Investment Counsel LLC Trims Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Grants County College of Morris Foundation $150,000 Towards New Center for Health Professions Building - TAPinto
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race - GlobeNewswire Inc.
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $161.00 - MarketBeat
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data - BioSpace
Mitsubishi UFJ Asset Management Co. Ltd. Has $287.48 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Intech Investment Management LLC Raises Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Q1 EPS Forecast Lifted by Zacks Research - MarketBeat
Fox Run Management L.L.C. Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy - BioSpace
Gilead Sciences (GILD) HIV Pill Shows Promising Results in Phase 3 Trials - GuruFocus
Gilead reports positive phase 3 data for HIV treatment combo - Investing.com
Gilead's BIC/LEN Pill Maintains Viral Suppression in HIV Trials - Intellectia AI
Gilead (GILD) Introduces Promising HIV Treatment in Phase 3 Tria - GuruFocus
Gilead's experimental HIV treatment shows low discontinuation rates in studies - Reuters
Gilead's New HIV Treatment Shows Promise in Phase 3 Trials - Intellectia AI
Gilead HIV drug combination maintains viral suppression in phase 3 trials - StreetInsider
Gilead paints clearer picture of next-gen HIV tablet's prowess with results from 2 late-stage studies - Fierce Pharma
Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's
Arcellx set to report earnings amid pending Gilead acquisition - Investing.com
Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating - marketscreener.com
UBS reiterates Buy on Gilead stock after Aclx acquisition - Investing.com
UBS reiterates Buy on Gilead stock after Aclx acquisition By Investing.com - Investing.com UK
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy - Benzinga
Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead… - marketscreener.com
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight - GuruFocus
Gilead to Acquire Arcellx for Up to $7.8 Billion, Doubling Down on Next-Generation CAR-T Therapy - NAI500
GILEAD SCIENCES, INC. SEC 10-K Report - TradingView
Arcellx Stock Explodes 77% After Gilead’s $7.8 Billion Takeover Announcement. Here’s What Investors Should Know - TIKR.com
Gilead Sciences acquires biotech company Arcellx for $7.8 billion - AKM.RU
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel - TradingView
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):